7 July 2017Big Pharma

UK Supreme Court rules against Actavis in Eli Lilly patent dispute

The UK Supreme Court has ruled that Actavis’s generic versions of cancer drug Alimta directly infringe patents owned by Eli Lilly, reversing two earlier decisions.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
4 April 2017   A five-year dispute between Eli Lilly and Actavis over a cancer drug is being heard today at the UK Supreme Court.
Big Pharma
12 July 2017   The UK Supreme Court has reformulated the three questions that should be asked when testing for equivalent patent infringement.

More on this story

Big Pharma
4 April 2017   A five-year dispute between Eli Lilly and Actavis over a cancer drug is being heard today at the UK Supreme Court.
Big Pharma
12 July 2017   The UK Supreme Court has reformulated the three questions that should be asked when testing for equivalent patent infringement.

More on this story

Big Pharma
4 April 2017   A five-year dispute between Eli Lilly and Actavis over a cancer drug is being heard today at the UK Supreme Court.
Big Pharma
12 July 2017   The UK Supreme Court has reformulated the three questions that should be asked when testing for equivalent patent infringement.